Zheng Xin, Chen Shulin, Li Linfang, Liu Xiaohua, Liu Xiaomin, Dai Shuqin, Zhang Peng, Lu Huaiwu, Lin Zhongqiu, Yu Yuefei, Li Guorong
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China.
Guangzhou Hengtai Biotech Ltd, 11 Kaiyuan Road, Guangzhou, Guangdong 510530, China.
J Gynecol Obstet Hum Reprod. 2018 Jun;47(6):227-230. doi: 10.1016/j.jogoh.2018.03.010. Epub 2018 Mar 30.
Serum human epididymis protein 4 (HE4) and transthyretin (TTR) are new markers for ovarian cancer. We compared HE4 and TTR with the gold marker CA-125 for the diagnosis of ovarian cancer patients.
One hundred and thirty serum samples from benign ovarian tumor and 400 serum samples from healthy women were used to set up the cut-off. One hundred and twenty-six serum samples from ovarian cancer patients before operation were collected to test the diagnostic value of these ELISA assays. The sensitivity, positive predictive value (PPV) and ROC curves were used to evaluate the diagnostic value.
For CA-125, the sensitivity and PPV were respectively 64.29% and 53.57% for stage I-II cancer patients, and respectively 91.43% and 88.57% for stage III-IV cancer patients. For HE4, the sensitivity and PPV were respectively 46.4% and 43.3% for stage I-II cancer patients, and respectively 88.6% and 49.2% for stage III-IV cancer patients. For TTR, the sensitivity and PPV were respectively 78.6% and 68.8% for stage I-II cancer patients, and respectively 82.9% and 74.3% for stage III-IV cancer patients. For CA125, the ROC was respectively 0.7941 and 0.9520 for stage I-II patients and stage III-IV patients. For HE4, the diagnostic value of ROC was 0.7071 for stage I-II cancer patients and 0.9250 for stage III-IV cancer patients. For TTR, the diagnostic value of ROC was 0.9112 for stage I-II cancer patients and 0.9322 for stage III-IV cancer patients.
Our results support that TTR is an efficient serum marker for the diagnosis of early stage ovarian cancer patients.
血清人附睾蛋白4（HE4）和转甲状腺素蛋白（TTR）是卵巢癌的新型标志物。我们将HE4和TTR与金标准标志物CA - 125进行比较，以诊断卵巢癌患者。
使用130份来自良性卵巢肿瘤的血清样本和400份来自健康女性的血清样本设定临界值。收集126份卵巢癌患者术前的血清样本，以检测这些酶联免疫吸附测定（ELISA）法的诊断价值。采用灵敏度、阳性预测值（PPV）和ROC曲线评估诊断价值。
对于CA - 125，I - II期癌症患者的灵敏度和PPV分别为64.29%和53.57%，III - IV期癌症患者分别为91.43%和88.57%。对于HE4，I - II期癌症患者的灵敏度和PPV分别为46.4%和43.3%，III - IV期癌症患者分别为88.6%和49.2%。对于TTR，I - II期癌症患者的灵敏度和PPV分别为78.6%和68.8%，III - IV期癌症患者分别为82.9%和74.3%。对于CA125，I - II期患者和III - IV期患者的ROC分别为0.7941和0.9520。对于HE4，I - II期癌症患者的ROC诊断价值为0.
